Eltrekibart Biosimilar Monoclonal Antibody (CXCL1/2/3/5/6/7/8) for Research

Cat No.: GMP-Bios-INN-1174

Anti-CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8 therapeutic antibody (Pre-made Eltrekibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Eltrekibart (development code LY3041658) is a humanized monoclonal antibody targeting ELR+ C-X-C chemokines including CXCL1 and CXCL8. It is developed by Eli Lilly for hidradenitis suppurativa. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1174-1mg 1mg 3090
GMP-Bios-INN-1174-10mg 10mg
GMP-Bios-INN-1174-100mg 100mg
GMP-Bios-INN-1174-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Eltrekibart biosimilar, Whole mAb, Anti-CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8 Antibody: Anti-CXCL1/Growth-regulated alpha protein/C-X-C motif chemokine 1/GRO-alpha(1-73) therapeutic antibody
INN Name Eltrekibart
Target CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure 6wzk:AB:CD/6wzl:AB:CD/6wzj:AB:CD/6wzm:AB:CD
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2024
Companies Eli Lilly
Conditions Approved na
Conditions Active Hidradenitis suppurative
Conditions Discontinued Skin disorders
Production na
Development Tech na